# A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07217301/  
OnCo record `nct07217301` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing TAK-928 in non-small-cell lung cancer, now recruiting.

## Summary

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07217301, led by Takeda with Innovent Biologics (Suzhou), and recruiting on the registry. Official title: A Randomised, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. Planned enrolment is 600 participants (estimated). The study started in 2025-11-26 and primary completion is expected in 2028-11-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: MarsLight-11
- Tags: ctgov-ingest
- Registry id: NCT07217301
- Phase: 3
- Setting: A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Sponsor: Takeda
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT07217301: https://clinicaltrials.gov/study/NCT07217301

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [TAK-928](https://onco.cc/drugs/tak-928/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/nct07217301.json